厄洛替尼二线治疗晚期非小细胞肺癌的临床观察  

Second-line therapy of erlotinib in advanced non-small cell lung cancer

作　　者：郝吉庆[1] 钱勇[1] 吴红阳[1] 

机构地区：[1]安徽医科大学第一附属医院肿瘤内科,合肥230022

出　　处：《临床肿瘤学杂志》2009年第8期701-703,共3页Chinese Clinical Oncology

摘　　要：目的:观察厄洛替尼(特罗凯)单药二线治疗国人晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法:28例晚期NSCLC患者口服厄洛替尼150mg/d治疗,连续服用2个月后,根据RECIST标准评价其近期疗效及NCI毒性评价标准评价不良反应。结果:28例患者中PR 5例(17.86%),SD 12例(42.86%),PD 11例(39.28%),有效率(CR+PR)为17.86%;疾病控制率(CR+PR+SD)为60.72%。肿瘤进展时间(TTP)为2～11个月,中位TTP为5.7个月;中位生存期(MST)为11.5个月。主要的毒副反应为皮疹、皮肤瘙痒、腹泻和恶心,多为Ⅰ～Ⅱ度,对症处理后可缓解。结论:厄洛替尼单药二线治疗国人晚期NSCLC疗效较好,且不良反应轻微。Objective：To evaluate the efficacy and the side effect of erlotinib as the second line therapy in the treatment of patients with advanced non-small cell lung cancer（NSCLC）.Methods：Twenty-eight patients with advanced NSCLC were treated with erlotinib which was given orally as a single drug at a dose of 150mg per day.The efficacy was evaluated according to RECIST criteria and the adverse events were evaluated according to NCI criteria.Results：There was no complete response（CR）,partial response（PR） 17.86%,stable disease（SD） 42. 86% , progressive disease（PD） 39. 28%. The response rate（ CR ＋ PR） was 17.86% , the disease control rate（ CR ＋ PR ＋ SD） was 60. 72% in the 28 cases. Time to progression（TTP） was 2-11 months, and median time to progession （mTYP） was 5.7 months. Median survival time（MST） was 11.5 months. The main side effects were rash and itch of skin, diarrhea and nausea, which could be relieved by treatment. Conclusion：It is effective and feasible to treat advanced NSCLC with erlotinib as the second line therapy.

关 键 词：非小细胞肺癌 厄洛替尼 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]